NO811908L - Nye imidazolderivater. - Google Patents
Nye imidazolderivater.Info
- Publication number
- NO811908L NO811908L NO811908A NO811908A NO811908L NO 811908 L NO811908 L NO 811908L NO 811908 A NO811908 A NO 811908A NO 811908 A NO811908 A NO 811908A NO 811908 L NO811908 L NO 811908L
- Authority
- NO
- Norway
- Prior art keywords
- formula
- imidazole
- acid addition
- butyl
- hydrogen
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims abstract description 16
- 150000003839 salts Chemical class 0.000 claims abstract description 16
- 239000002253 acid Substances 0.000 claims abstract description 13
- 239000001257 hydrogen Substances 0.000 claims abstract description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 7
- -1 methylenedioxy Chemical group 0.000 claims abstract description 7
- 239000011737 fluorine Chemical group 0.000 claims abstract description 6
- 229910052731 fluorine Chemical group 0.000 claims abstract description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 6
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims abstract description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 3
- 150000002460 imidazoles Chemical class 0.000 claims abstract description 3
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 claims abstract description 3
- 125000001544 thienyl group Chemical group 0.000 claims abstract description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract 2
- 239000003054 catalyst Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 150000002431 hydrogen Chemical class 0.000 claims description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- ZVPUTQRPIGBFSE-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-yl)-4,5-ditert-butyl-1h-imidazole Chemical compound N1C(C(C)(C)C)=C(C(C)(C)C)N=C1C1=CC=C(OCO2)C2=C1 ZVPUTQRPIGBFSE-UHFFFAOYSA-N 0.000 claims description 2
- HVKHQIAZUKEEHQ-UHFFFAOYSA-N 4,5-ditert-butyl-1-methyl-2-phenylimidazole Chemical compound CC(C)(C)C1=C(C(C)(C)C)N(C)C(C=2C=CC=CC=2)=N1 HVKHQIAZUKEEHQ-UHFFFAOYSA-N 0.000 claims description 2
- KKYBZAXMEQXGCV-UHFFFAOYSA-N 4,5-ditert-butyl-2-(3,4,5-trimethoxyphenyl)-1h-imidazole Chemical compound COC1=C(OC)C(OC)=CC(C=2NC(=C(N=2)C(C)(C)C)C(C)(C)C)=C1 KKYBZAXMEQXGCV-UHFFFAOYSA-N 0.000 claims description 2
- DRLQKHVQGHIZSB-UHFFFAOYSA-N 4,5-ditert-butyl-2-phenyl-1h-imidazole Chemical compound N1C(C(C)(C)C)=C(C(C)(C)C)N=C1C1=CC=CC=C1 DRLQKHVQGHIZSB-UHFFFAOYSA-N 0.000 claims description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 2
- 238000006477 desulfuration reaction Methods 0.000 claims description 2
- 230000023556 desulfurization Effects 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 4
- 238000002360 preparation method Methods 0.000 claims 2
- UQFDAFJUGIDCQS-UHFFFAOYSA-N 4,5-ditert-butyl-2-(7-methoxy-1,3-benzodioxol-5-yl)-1h-imidazole Chemical compound C=1C=2OCOC=2C(OC)=CC=1C1=NC(C(C)(C)C)=C(C(C)(C)C)N1 UQFDAFJUGIDCQS-UHFFFAOYSA-N 0.000 claims 1
- 235000013312 flour Nutrition 0.000 claims 1
- 238000004220 aggregation Methods 0.000 abstract description 5
- 230000002776 aggregation Effects 0.000 abstract description 5
- 210000001772 blood platelet Anatomy 0.000 abstract description 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 9
- 238000000354 decomposition reaction Methods 0.000 description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 238000003756 stirring Methods 0.000 description 7
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- GFZNLWBRSSKIQN-UHFFFAOYSA-N 3,3,6,6-tetramethylthiepane-4,5-dione Chemical compound CC1(C)CSCC(C)(C)C(=O)C1=O GFZNLWBRSSKIQN-UHFFFAOYSA-N 0.000 description 2
- UKMWFZPCIIIDOT-UHFFFAOYSA-N 4,4,8,8-tetramethyl-2-phenyl-5,7-dihydro-1h-thiepino[4,5-d]imidazole Chemical compound N=1C=2C(C)(C)CSCC(C)(C)C=2NC=1C1=CC=CC=C1 UKMWFZPCIIIDOT-UHFFFAOYSA-N 0.000 description 2
- LPFVCMFYXQTBQV-UHFFFAOYSA-N 4,5-ditert-butyl-2-(4-fluorophenyl)-1h-imidazole Chemical compound N1C(C(C)(C)C)=C(C(C)(C)C)N=C1C1=CC=C(F)C=C1 LPFVCMFYXQTBQV-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 1
- VPEFXNWRCVMKKG-UHFFFAOYSA-N 4,5-ditert-butyl-2-(4-methoxyphenyl)-1h-imidazole Chemical compound C1=CC(OC)=CC=C1C1=NC(C(C)(C)C)=C(C(C)(C)C)N1 VPEFXNWRCVMKKG-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000008046 alkali metal hydrides Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001734 carboxylic acid salts Chemical class 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Fats And Perfumes (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Epoxy Resins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH434780 | 1980-06-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO811908L true NO811908L (no) | 1981-12-07 |
Family
ID=4274400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO811908A NO811908L (no) | 1980-06-05 | 1981-06-04 | Nye imidazolderivater. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US4582844A (da) |
| EP (1) | EP0041652B1 (da) |
| JP (1) | JPS5731667A (da) |
| KR (1) | KR850000126B1 (da) |
| AT (1) | ATE6369T1 (da) |
| AU (1) | AU7111581A (da) |
| BR (1) | BR8103553A (da) |
| CA (1) | CA1161847A (da) |
| CS (1) | CS220340B2 (da) |
| DE (1) | DE3162356D1 (da) |
| DK (1) | DK193181A (da) |
| ES (1) | ES502777A0 (da) |
| FI (1) | FI811527L (da) |
| GR (1) | GR77076B (da) |
| IL (1) | IL63009A0 (da) |
| MC (1) | MC1394A1 (da) |
| NO (1) | NO811908L (da) |
| NZ (1) | NZ197248A (da) |
| PH (1) | PH15876A (da) |
| PT (1) | PT73143B (da) |
| ZA (1) | ZA813644B (da) |
| ZW (1) | ZW10781A1 (da) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4501892A (en) * | 1982-07-28 | 1985-02-26 | The Upjohn Company | Pyridyl benzenediols |
| IT1193608B (it) * | 1983-01-21 | 1988-07-21 | Pierrel Spa | Derivati di arilossipropanolamina,procedimento per la loro preparazione composizioni farmaceutiche che li contengono e loro impiego terapeutico |
| US4790775A (en) * | 1988-02-09 | 1988-12-13 | E. I. Du Pont De Nemours And Company | Transition connector |
| US8182528B2 (en) | 2003-12-23 | 2012-05-22 | Sadra Medical, Inc. | Locking heart valve anchor |
| JP6064653B2 (ja) * | 2013-02-15 | 2017-01-25 | 東洋インキＳｃホールディングス株式会社 | 蛍光材料、蛍光性樹脂組成物および化合物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE585507A (da) * | 1960-03-31 | |||
| US3473901A (en) * | 1963-02-08 | 1969-10-21 | Rohm & Haas | Fuel compositions |
| CH496710A (de) * | 1967-12-16 | 1970-09-30 | Basf Ag | Verfahren zur Herstellung von substituierten Imidazolen |
| DD99787A1 (da) * | 1969-06-23 | 1973-08-20 | ||
| US3707475A (en) * | 1970-11-16 | 1972-12-26 | Pfizer | Antiinflammatory imidazoles |
| DE2701372A1 (de) * | 1977-01-14 | 1978-07-20 | Veba Chemie Ag | Verfahren zur herstellung cyclischer amidine |
| DE2733466A1 (de) * | 1977-07-25 | 1979-02-22 | Basf Ag | Verfahren zur herstellung von imidazolen |
-
1981
- 1981-04-30 DK DK193181A patent/DK193181A/da not_active Application Discontinuation
- 1981-05-07 ZW ZW107/81A patent/ZW10781A1/xx unknown
- 1981-05-08 CA CA000377230A patent/CA1161847A/en not_active Expired
- 1981-05-14 CS CS813581A patent/CS220340B2/cs unknown
- 1981-05-18 FI FI811527A patent/FI811527L/fi not_active Application Discontinuation
- 1981-05-27 AT AT81104077T patent/ATE6369T1/de not_active IP Right Cessation
- 1981-05-27 EP EP81104077A patent/EP0041652B1/de not_active Expired
- 1981-05-27 DE DE8181104077T patent/DE3162356D1/de not_active Expired
- 1981-05-28 AU AU71115/81A patent/AU7111581A/en not_active Abandoned
- 1981-05-29 ZA ZA00813644A patent/ZA813644B/xx unknown
- 1981-05-29 NZ NZ197248A patent/NZ197248A/en unknown
- 1981-06-01 IL IL63009A patent/IL63009A0/xx unknown
- 1981-06-02 JP JP8392681A patent/JPS5731667A/ja active Pending
- 1981-06-03 MC MC811517A patent/MC1394A1/xx unknown
- 1981-06-03 GR GR65141A patent/GR77076B/el unknown
- 1981-06-04 NO NO811908A patent/NO811908L/no unknown
- 1981-06-04 ES ES502777A patent/ES502777A0/es active Granted
- 1981-06-04 PH PH25717A patent/PH15876A/en unknown
- 1981-06-04 PT PT73143A patent/PT73143B/pt unknown
- 1981-06-04 BR BR8103553A patent/BR8103553A/pt unknown
- 1981-06-04 KR KR1019810002007A patent/KR850000126B1/ko active
-
1985
- 1985-09-10 US US06/774,393 patent/US4582844A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA1161847A (en) | 1984-02-07 |
| BR8103553A (pt) | 1982-03-02 |
| US4582844A (en) | 1986-04-15 |
| ZW10781A1 (en) | 1981-12-30 |
| ES8300755A1 (es) | 1982-11-16 |
| ATE6369T1 (de) | 1984-03-15 |
| DK193181A (da) | 1981-12-06 |
| CS220340B2 (en) | 1983-03-25 |
| GR77076B (da) | 1984-09-06 |
| NZ197248A (en) | 1984-07-31 |
| PH15876A (en) | 1983-04-13 |
| ZA813644B (en) | 1982-06-30 |
| KR830006229A (ko) | 1983-09-20 |
| IL63009A0 (en) | 1981-09-13 |
| MC1394A1 (fr) | 1982-04-27 |
| PT73143B (en) | 1983-05-11 |
| PT73143A (en) | 1981-07-01 |
| KR850000126B1 (ko) | 1985-02-27 |
| JPS5731667A (en) | 1982-02-20 |
| AU7111581A (en) | 1981-12-10 |
| DE3162356D1 (en) | 1984-03-29 |
| EP0041652A1 (de) | 1981-12-16 |
| EP0041652B1 (de) | 1984-02-22 |
| FI811527L (fi) | 1981-12-06 |
| ES502777A0 (es) | 1982-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0385237B1 (en) | 2-(1-piperazinyl)-4-phenylcycloalkanopyridine derivatives, processes for the production thereof, and pharmaceutical composition containing the same | |
| US4554280A (en) | Pyridyl methyl thio or sulfinyl indeno(5,6-d)imidazoles | |
| EP0580541B1 (en) | Piperidine derivatives of benzimidazole as antihistaminic and antiallergic agents | |
| US4560693A (en) | [1,3]-Dioxolo[4,5-f]benzimidazoles and [1,4]-dioxino[2,3-f]benzimidazoles | |
| WO1997047601A1 (fr) | Composes heterocycliques fusionnes et leurs utilisations medicinales | |
| HU194209B (en) | Process for preparing novel pyridine-2-ether derivatives and pyridine-2-thioether derivative having nitrogen-containing cycloaliphatic ring and pharmaceuticals comprising the same | |
| SK154196A3 (en) | Piperazine derivatives, preparation method thereof and their use as 5ht1a antagonists | |
| SK280812B6 (sk) | 1,3-substituované cykloalkány a 1,3-substituované cykloalkény, spôsoby ich prípravy a farmaceutické prípravky na ich báze | |
| US4732984A (en) | Piperazinoisothiazolones with psychotropic activity | |
| AU593844B2 (en) | N-substituted diphenylpiperidines | |
| EP0105397B1 (de) | Schwefelhaltige Indolderivate | |
| NO811908L (no) | Nye imidazolderivater. | |
| AU596869B2 (en) | 2-(thio-linked)-pyridine-5-(4,5-dihydro-2-oxazolyl)-(thieno( 2,3-d)-imidazoles and -benzimidazoles), a process for their preparation, and their use | |
| EP0164633A2 (de) | Indolderivate | |
| US4001271A (en) | 3-(isopropyl amino alkoxy)-2-phenyl-isoindolin-1-ones | |
| NO801843L (no) | Nye kinazolinderivater og farmasoeytiske preparater | |
| DE3308668A1 (de) | Indolderivate | |
| SK175298A3 (en) | Indoline derivatives useful as 5-ht-2c receptor antagonists | |
| US4672064A (en) | 1,5-benzoxathiepin derivatives, their production and use | |
| EP0128021B1 (en) | Tetrahydro-beta-carboline derivatives and process for the preparation thereof | |
| JPS61100579A (ja) | ピリジン誘導体 | |
| US4167571A (en) | Thiazoline derivatives | |
| KR100917041B1 (ko) | 5-ｈｔ7 수용체에 길항작용을 갖는 신규한 화합물 | |
| KR840002140B1 (ko) | 이미다졸 유도체의 제조방법 | |
| DK151632B (da) | Analogifremgangsmaade til fremstilling af 4,5,7,8-tetrahydro-4,4,8,8-tetramethyl-1-h-thiepinooe4,5-daaimidazolderivater |